Named peptide stack · Sexual Health Peptides
Sexual Health Stack
The Sexual Health Stack pairs PT-141 (Bremelanotide, FDA-approved in the US for premenopausal HSDD as Vyleesi) with Kisspeptin (research compound under active UK clinical investigation at Imperial College London). UK regulatory status for both is research-tier outside of clinical trial enrolment.
Why researchers pair these compounds
PT-141 acts on central-nervous-system melanocortin receptors. Mechanism is CNS arousal modulation, distinct from peripheral vascular action of PDE5 inhibitors like sildenafil. FDA-approved as Vyleesi in the US for premenopausal Hypoactive Sexual Desire Disorder.
Kisspeptin sits upstream of the reproductive endocrine axis, regulating GnRH release. UK clinical-research lead is the Waljit Dhillo lab at Imperial College London with active trial work in HSDD and IVF triggering.
Both are not UK-licensed medicines outside of clinical trial settings.
Mechanism
PT-141 melanocortin-receptor agonism at CNS MC1R and MC4R. Kisspeptin agonism at hypothalamic KISS1R receptors, driving GnRH release and downstream LH and FSH from the pituitary.
Components
Kisspeptin
GnRH-axis regulator. Active UK clinical trial research at Imperial College London.
Encyclopedia entryWho this is for
- · Researchers studying CNS arousal pathways or reproductive-axis regulation in preclinical or clinical-trial settings.
UK retailers stocking the components
See CoA Trust Index →Ranked by CoA Trust tier. Editorial commentary based on publicly available information. We earn a referral fee when readers click through and convert.
Researchers wanting GLP-1-adjacent compounds (Tirzepatide, Retatrutide, Mazdutide) inside a broader peptide catalogue, plus an adjacent biomarker blood-test service.
Research peptide retailer · BPC-157 £17.99, Tirzepatide from £42.99
Anti-counterfeit-framed UK research peptide retailer leaning hard on Fat Loss as primary nav category (Tirzepatide, Retatrutide, Mazdutide) alongside the broader catalogue. Above 99 percent HPLC and mass-spec verified purity claim. CoA gated by email request. Long-form pillar guides with named author byline and PubMed citations.
Buyers wanting the broadest catalogue of delivery formats (vials + pens + nasals + capsules + topicals) in the UK segment.
Research peptide retailer (US parent, UK subdomain) · BPC-157 £11.46 to £189.22 (volume tiers per SKU)
UK-localised subdomain of US-headquartered Direct Peptides (trademark held by Aspire Labs, Texas). Broadest format coverage in the UK segment: lyophilised vials, pre-mixed pens, nasal-spray stacks, capsules, topical cosmetic peptides. 8 years trading (since ~2017). 20 percent first-order discount on dedicated /first-order/ page.
Frequently asked questions
Is PT-141 the same as Viagra?
No. Different mechanism. PT-141 acts on CNS arousal pathways via melanocortin receptors. Sildenafil (Viagra) acts on peripheral vascular smooth muscle via PDE5 inhibition. Not interchangeable.
Can I get PT-141 on the NHS?
No. PT-141 is not UK-licensed. The US-approved Vyleesi has no UK marketing authorisation.
PeptideClear does not sell, dispense, prescribe, or recommend Sexual Health Stack for any specific person. This page is editorial commentary on the published preclinical literature and the UK retail landscape. Every research peptide on this page is sold under research-use-only framing.
Read our full methodology and how we are funded.
Ready to buy
Shop UK peptides, collagen and GLP-1 routes
Compare UK retailers, clinics and pharmacies across every PeptideClear category.